CED-Studienzentrum Karlshorst

The CED-Studienzentrum Karlshorst specializes in Immune System Diseases and is actively investigating Crohn's Disease in patients with moderate to severe activity.

• Biologic combination therapy
• Subcutaneous induction strategies
• Long‑term efficacy and safety monitoring
• Endoscopic response and remission outcomes

Located in Berlin, the site conducts innovative studies to expand treatment options for individuals living with Crohn's disease.

One study evaluates the synergistic potential of guselkumab together with golimumab as a combination therapy for patients with moderately to severely active Crohn's disease.

• IL‑23 and TNF‑α pathway inhibition
• Clinical remission rates at 48 weeks
• Comparative safety profile
• Patient‑reported quality of life measures

The trial seeks to determine whether targeting multiple inflammatory pathways improves disease control beyond standard monotherapy.

Another Phase 3 investigation focuses on the efficacy of guselkumab administered as a subcutaneous induction regimen, aiming for rapid clinical remission in Crohn's disease.

• Induction dosing schedule
• Endoscopic healing assessment
• Patient‑reported outcomes and symptom relief
• Safety and tolerability over the induction period

This research expands the therapeutic toolbox by exploring a targeted biologic that may offer faster and sustained disease improvement.